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Abstract 
A HPLC method has been described for simultaneous determination of 
Losartan potassium and Metolazone in formulation. This method is based on a 
HPLC separation of the two drugs on the Thermo Hypersil BDS–C18 (250 mm × 
4.6 mm, 5.0 µm) with isocratic conditions and a simple mobile phase containing 
acetonitrile:water (60:40) at a flow rate of 0.8 mL/min using UV detection at 
237 nm. This method has been applied to a marketed  formulation without 
interference of excipients. The linear regression analysis data for the calibration 
plots showed a good linear relationship over the concentration range of 2–12 
µg/mL for Losartan potassium and 0.2–1.2 µg/mL for Metolazone, respectively. 
The method was validated for precision, robustness and recovery. Statistical 
analysis showed that the method is repeatable and selective for the estimation 
of Losartan potassium and Metolazone.  
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Introduction  
Losartan potassium is chemically potassium 5-(4'-{[2-butyl-4-chloro-5-(hydroxymethyl)-1H-
imidazol-1-yl]methyl}biphenyl-2-yl)tetrazol-1-ide (Figure 1a) [1]. It is a strong non-peptide 
antihypertensive agent, which exerts its action by specific blocking of angiotensin II 
receptors. It has a gradual, long-lasting effect as an antihypertensive.  546  R. Dubey, V. K. Bhusari, and S. R. Dhaneshwar:   
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Metolazone is chemically 7-chloro-2-methyl-3-(2-methylphenyl)-4-oxo-1,2,3,4-tetrahydro-
quinazoline-6-sulfonamide [2, 3]  (Figure  1b).  Metolazone is an oral diuretic drug, 
commonly classified with the thiazide diuretics. It is primarily used to treat congestive heart 
failure and high blood pressure. Metolazone indirectly decreases the amount of water 
reabsorbed into the bloodstream by the kidney, so that blood volume decreases and urine 
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Fig. 1.  Structures of Losartan potassium (a) and Metolazone (b) 
Hence, the combination of Losartan potassium and Metolazone (extended release), such 
as in the marketed product Metoz
©, complements each other and provides an additive 
effect on blood pressure control, which is sustained for at least 24 hours. 
Literature review reveals that methods have been reported for analysis of Losartan 
potassium and Metolazone,  HPLC method for determination of Losartan potassium  in 
combination with other drugs [4–6] and few bioanalytical methods are also reported [7–10]. 
RP-HPLC method for determination of Metolazone [11] and few bioanalytical methods are 
also reported [12–14]. 
To date, there have been no published reports about the simultaneous quantitation of 
Losartan potassium and Metolazone by HPLC in bulk drug and in tablet dosage form. This 
present study reports for the first time simultaneous quantitation of Losartan potassium 
and Metolazone by RP-HPLC in bulk drug and in tablet dosage form. The proposed 
method is validated as per ICH guidelines [15–17].  
Experimental 
Materials 
Centaur Pharmaceuticals Pvt. Ltd. Ambarnath, India, kindly supplied pure drug sample of 
Losartan potassium as a gift sample of Batch No.: LTP/100/002 and Metolazone of Batch 
No.: 2010360IP. It was used without further purification and certified to contain 99.60 % 
(w/w)  for Losartan potassium and 99.70 % (w/w) for Metolazone on dried basis. All 
chemicals and reagents used were of HPLC grade and were purchased from Merck 
Chemicals, India. 
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Instrumentation  
The HPLC system consisted of a Pump (model Jasco PU 2080), Intelligent LC pump with 
sampler programmed at 20 µL capacity per injection was used. The detector consisted of 
UV/ VIS (Jasco UV 2075) model operated at a wavelength of 237 nm. Data was integrated 
using Jasco Borwin version 1.5, LC-Net II/ADC system. The column used was a Thermo 
Hypersil BDS–C18 (250 mm × 4.6 mm, 5.0 µm) from Germany. 
Preparation of Standard Stock Solutions  
Standard stock solution of concentration 100 µg/mL of Losartan potassium and 10 µg/mL 
of  Metolazone was prepared using acetonitrile. From the standard stock solution, the 
mixed standard solutions were prepared using mobile phase (acetonitrile:water in the ratio 
60:40 v/v) to contain 20 µg/mL of Losartan potassium and 2 µg/mL of Metolazone. The 
stock solution was stored at 2–8 °C protected from light.  
Optimization of HPLC Method  
The HPLC procedure was optimized with a view to develop a simultaneous assay method 
for Losartan potassium and Metolazone respectively. The mixed standard stock solution 
(20 µg/mL of Losartan potassium and 2 µg/mL of Metolazone) was injected in HPLC. For 
HPLC method optimization different ratios of methanol and water were tried but it was 
found that the peaks got distorted when methanol was used. Hence, methanol was 
replaced with acetonitrile. Different ratios of acetonitrile and water were tried. It was found 
that acetonitrile: water in the ratio 60:40 v/v at flow rate 1.0 mL/min gave good peak shape 
but it was found that the drugs eluted in dead volume. Hence the flow rate was reduced to 
0.8 mL/min which gave acceptable retention time (tR) of 2.57 and 4.81, the plate count was 
found to be 4950 and 5548 and good resolution for Losartan potassium and Metolazone, 
respectively (Figure 2). 
 
Fig. 2.   HPLC chromatogram of standard Losartan potassium and Metolazone 
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Validation of the method  
Validation of the optimized HPLC method was carried out with respect to: 
Linearity and range 
The mixed standard stock solution (100 µg/mL of Losartan potassium and 10 µg/mL of 
Metolazone) was further diluted to get Losartan potassium and Metolazone concentration 
in the range of 2–12 µg/mL and 0.2–1.2 µg/mL respectively. Linearity of the method was 
studied by injecting six concentrations of the drug prepared in the mobile phase in triplicate 
into the LC system keeping the injection volume constant. The peak areas were plotted 
against the corresponding concentrations to obtain the calibration graphs.  
Precision 
The precision of the method was verified by repeatability and intermediate precision 
studies. Repeatability studies were performed by analysis of three different concentrations 
2, 6, 10 µg/mL for Losartan potassium and 0.2, 0.6, 1.0 µg/mL for Metolazone six times on 
the same day. The intermediate precision of the method was checked by repeating studies 
on three different days.  
Limit of detection and limit of quantitation 
Limits of detection (LOD) and quantification (LOQ) represent the concentration of the 
analyte that would yield signal-to-noise ratios of 3 for LOD and 10 for LOQ, respectively. 
To determine the LOD and LOQ, serial dilutions of mixed standard solution of Losartan 
potassium and Metolazone was made from the standard stock solution. The samples were 
injected in LC system and measured signal from the samples was compared with those of 
blank samples. 
Robustness of the method  
To evaluate robustness of a HPLC method, few parameters were deliberately varied. The 
parameters included variation of flow rate, percentage of acetonitrile in the mobile phase 
and solvents from different lot were taken. Robustness of the method was done at three 
different concentration levels 2, 6, 10 µg/mL  and 0.2, 0.6, 1.0  µg/mL for Losartan 
potassium and Metolazone respectively.  
Specificity 
The specificity of the method towards the drug was established through study of resolution 
factor of the drug peak from  the nearest  resolving peak.The peak purity of Losartan 
potassium and Metolazone was determined by comparing the spectrum at three different 
regions of the peak  i.e. peak start (S), peak apex (M) and peak end (E). Effect of 
excipients of formulation was studied for whether it interfered with the assay.  
Accuracy 
Accuracy of the method was determined by applying the method to drug sample (Losartan 
potassium and Metolazone combination tablet) to which known  amount of Losartan 
potassium and Metolazone standard powder corresponding to 80, 100 and 120 % of label 
claim had been added (Standard addition method), mixed and the powder was extracted 
and analyzed by running chromatogram in optimized mobile phase.   Validated RP-HPLC Method for Simultaneous Quantitation of Losartan Potassium and Metolazone …  549 
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Analysis of a marketed formulation 
To determine the content of Losartan potassium and Metolazone in conventional tablet 
(Brand name: METOZ – L 25, Batch No. 107, Label claim: 25 mg Losartan potassium and 
2.5 mg Metolazone per tablet, Manufactured by: Centaur Pharmaceutical Pvt. Ltd., GOA), 
twenty tablets were weighed  to determine the main weight  and finely powdered. The 
weight of the tablet triturate equivalent to 25 mg of Losartan potassium and 2.5 mg 
Metolazone was transferred into a 50 mL volumetric flask containing 30 mL acetonitrile, 
sonicated for 30 min and diluted upto 50 mL with acetonitrile. The resulting solution was 
centrifuged at 3000 rpm for 5 min and the drug content of the supernatant was determined 
(500 and 50 µg/mL for  Losartan potassium and Metolazone respectively).  Supernatant 
was taken and after suitable dilution the sample solution was then filtered using 0.45-
micron filter (Millipore, Milford, MA). The above stock solution was further diluted with 
mobile phase (acetonitrile: water in the ratio 60:40 v/v) to get sample solution of 25 and 2.5 
µg/mL for Losartan potassium and Metolazone respectively. A 20 µL volume of sample 
solution was injected into HPLC, six times, under the conditions described above. The 
peak areas were measured at 237 nm and concentrations in the samples were determined 
using multilevel calibration developed on the same HPLC system under the same 
conditions using linear regression equation. 
Results and discussion 
The results of validation studies on simultaneous estimation method developed for 
Losartan potassium and Metolazone in the current study involving acetonitrile: water 
(60:40, v/v) are given below. 
Linearity 
Losartan potassium and Metolazone showed good correlation coefficient (r
2 = 0.9993 for 
Losartan potassium and 0.9991 for Metolazone) in given concentration range (2–12 µg/mL 
for  Losartan potassium and 0.2–1.2 µg/mL  for  Metolazone).  The mean values of the 
correlation coefficient, slope and intercept were 0.9993 ± 0.55, 18319 ± 1.18 and 458605 ± 
1.82 for Losartan potassium and 0.9991 ± 0.75, 124101 ± 1.21 and 313054 ± 1.09 for 
Metolazone respectively. 
Tab. 1.  Precision studies 
Concentration 
(µg/mL) 
Repeatability (n=6)  Intermediate precision (n=6) 
Measured 
conc. ±SD 




(%) RSD  Recovery 
(%) 
Losartan potassium 
2  1.99 ± 1.10  1.62  99.50  1.98 ± 0.76  1.52  99.00 
6  5.90 ± 1.20  0.90  98.33  5.98 ± 1.03  1.17  99.66 
10  9.97 ± 1.80  0.95  99.70  10.10 ± 1.84  1.32  101.00 
Metolazone 
0.2  0.198 ± 0.59  0.85  99  0.201 ± 0.72  0.91  100.5 
0.6  0.598 ± 1.85  1.04  99.66  0.605 ± 1.77  0.76  100.83 
1  0.99 ± 2.65  0.89  99.00  1.01 ± 2.34  0.66  101.00 
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Precision 
The results of the repeatability and intermediate precision experiments are  shown in 
(Table 1).  The developed method was found to be precise as the RSD values for 
repeatability and intermediate precision studies were < 2 %, respectively as recommended 
by ICH guidelines.  
LOD and LOQ 
Signal-to-noise ratios of 3:1 and 10:1 were obtained for the LOD and LOQ respectively. 
The LOD and LOQ were found to be 1 μg/mL and 2 μg/mL for Losartan potassium and 
0.01 μg/mL and 0.02 μg/mL Metolazone respectively. 
Tab. 2.  Robustness testing
a (n = 3) 
Factor
a  Level  Retention time  Retention factor  Asymmetry 
Losartan potassium 
A: Flow rate (mL/min) 
0.7  −1  2.60  0.04  1.19 
0.8  0  2.57  0.03  1.15 
0.9  +1  2.51  0.01  1.11 
Mean ± SD (n = 3)    2.56 ± 0.07  0.02 ± 0.01  1.15 ± 0.04 
B: % of acetonitrile in the mobile phase (v/v) 
59  −1  2.61  0.04  1.18 
60  0  2.57  0.03  1.15 
61  +1  2.52  0.08  1.12 
Mean ± SD (n = 3)    2.56 ± 0.05  0.05 ± 0.01  1.15 ± 0.03 
C: Solvents of different lots 
First lot 
  2.55  0.02  1.15 
Second lot 
  2.57  0.03  1.17 
Mean ± SD (n = 3) 
  2.56 ± 0.01
  0.02 ± 0.01
  1.16 ± 0.01
 
Metolazone 
A: Flow rate (mL/min) 
0.7  −1  4.85  0.94  1.15 
0.8  0  4.81  0.92  1.11 
0.9  +1  4.78  0.91  1.07 
Mean ± SD (n = 3)    4.81 ± 0.05  0.92 ± 0.01  1.11 ± 0.04 
B: % of acetonitrile in the mobile phase (v/v) 
61  −1  4.84  0.93  1.16 
60  0  4.81  0.92  1.11 
86  +1  4.79  0.91  1.06 
Mean ± SD (n = 3)    4.81 ± 0.06  0.92 ± 0.02  1.11 ± 0.05 
C: Solvents of different lots 
First lot 
  4.81  0.92  1.11 
Second lot 
  4.80  0.92  1.10 
Mean ± SD (n = 3) 
  4.80 ± 0.01
  0.92 ± 0.01
  1.10 ± 0.01
 
a Three factors were slightly changed at three levels (−1, 0, 1). 
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Robustness of the method 
Each factor selected (except columns from different manufacturers) was changed at three 
levels (−1, 0 and 1). One factor at the time was changed to estimate the effect. Thus, 
replicate injections (n = 6) of mixed standard solution at three concentration levels were 
performed under small changes of three chromatographic parameters (factors). 
Insignificant differences in peak areas and less variability in retention time were observed 
(Table 2).  
Specificity 
The peak purity of Losartan potassium and Metolazone was assessed by comparing their 
respective spectra at the peak start, apex and peak end positions i.e., r (S, M) = 0.9989 
and r (M, E) = 0.9989. A good correlation (r = 0.9997) was also obtained between the 
standard and sample spectra of Losartan potassium and Metolazone respectively. Also, 
excipients from formulation were not interfering with the assay. 
Recovery Studies 
As shown from the data in  Table 3, good recoveries of Losartan potassium and 
Metolazone in the range from 99 to 101% were obtained at various added concentrations.  









(mg) ± % RSD 
% Recovery 
Losartan potassium 
25  20 (80%)  45  44.98 ± 0.96  99.91 
25  25 (100%)  50  50.10 ± 1.01  100.20 
25  30 (120%)  55  55.20 ± 0.78  100.36 
Metolazone 
2.5  2.0 (80%)  4.5  4.48 ± 1.16  99.84 
2.5  2.5 (100%)  5.0  5.05 ± 1.40  101.00 
2.5  3.0 (120%)  5.5  5.52 ± 0.98  100.36 
 
Tab. 4.  Analysis of commercial formulation 
Losartan potassium  
(25 mg) 
Losartan potassium found (mg per tablet) 
Mean ± SD (n= 6)  Recovery (%) 
1
st Lot  24.85 ± 1.06  99.40 
2
nd Lot  24.90 ± 0.94  99.60 
Metolazone  
(2.5 mg) 
Metolazone found (mg per tablet) 
Mean ± SD (n= 6)  Recovery (%) 
1
st Lot  2.48 ± 1.16  99.20 
2
nd Lot  2.49 ± 1.04  99.60 
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Analysis of a formulation 
Experimental results show that there is no interference from any of the excipients which 
are normally present with that of standard Losatan potassium and Metolazone (Figure 3). 
The drug content was found to be 99.50%  for  Losartan potassium and 99.40% for 
Metolazone. Two different lots of Losartan potassium and Metolazone combination tablets 
were analyzed using the proposed procedures as shown in (Table 4). 
 
Fig. 3.  HPLC chromatogram of pharmaceutical formulation of Losartan potassium and 
Metolazone (20 µg/mL and 2 µg/mL) 
Conclusion  
A  HPLC method was developed and validated as per ICH guidelines. UV detection 
allowed an accurate quantitation of the chromophoric compounds. 
The drug was analysed by HPLC method using Thermo Hypersil BDS–C18 (250 mm × 4.6 
mm, 5.0 µm) from Germany with isocratic conditions and simple mobile phase containing 
acetonitrile: water (60:40) at flow rate of 0.8 mL/min using UV detection at 237 nm. The 
procedure has been evaluated for the linearity, accuracy, precision and robustness in 
order to ascertain the suitability of the analytical method. The method was also applied to 
marketed samples. It has been proved that the method is selective and linear between 
concentration range 2–12  μg/mL  for  Losartan potassiumand 0.2–1.2  μg/mL  for 
Metolazone.  LOD  was  found  to  be  1  μg/mL  and  LOQ  was  found  to  be  2  μg/mL  for 
Losartan potassium and LOD was found to be 0.01 μg/mL and LOQ was found to be 0.02 
μg/mL for Metolazone. 
Statistical analysis proves that the method is suitable for the analysis of Losartan 
potassium and Metolazone as bulk drug and in pharmaceutical formulation without any 
interference from the excipients. It may be extended to study the degradation kinetics of   Validated RP-HPLC Method for Simultaneous Quantitation of Losartan Potassium and Metolazone …  553 
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Losartan potassium and Metolazone and also for its estimation in plasma and other 
biological fluids. 
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